Adult
Eurartesim® (Piperaquine phosphate with artenimol)
Warning
General Information
Antimalarial
Piperaquine phosphate with artenimol
Unlicensed Restricted formulary antimicrobial: Must be recommended/prescribed by a Micro/ID consultant or registrar.
For all information regarding contraindications, cautions, interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Standard dose
| Weight | Oral dose |
| 75kg and above | 4 tablets* once daily for 3 days |
| 36-74 kg | 3 tablets* once daily for 3 days |
*Each tablet contains 320mg piperaquine phosphate and 40mg artenimol.
No more than two courses of Eurartesim® should be given in a 12-month period. If a second course is required, it should be given at least 2 months after the first course due to the long elimination half-life of piperaquine.
Renal and hepatic impairment
Renal impairment
- Caution in moderate to severe impairment (no information available) - monitor ECG and plasma potassium concentration
Hepatic impairment
- Caution in jaundice or in moderate to severe impairment (no information available) - monitor ECG and plasma potassium concentration.
Interactions
- Eurartesim® interacts with many drugs. Please refer to BNF and SPC for more information.
Additional information
- For monitoring information, including QTc, see BNF and SPC.
- Discharge letters to primary care should document Eurartesim® treatment, including doses and administration dates, due to its long half-life (t1/2 22 days).
References
- Eurartesim 160 mg/20 mg film-coated tablets summary of product characteristics. Accessed via European Medicines Agency from https://www.ema.europa.eu/en/documents/product-information/eurartesim-epar-product-information_en.pdf Accessed 11/9/26
- British National Formulary. Piperaquine phosphate with artenimol. BNF online accessed via www.medicinescomplete.com Accessed 11/9/26.